Clinical Trial

Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to study the drug LPX-TI641 in patients with rheumatoid arthritis and psoriatic arthritis. We will compare the safety and tolerability of LPX-TI641 to placebo that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-10-02; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-02-27
Trial Details
NCT Number NCT06628206
Lead Sponsor LAPIX Therapeutics Inc.
Conditions Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Enrollment 48 participants
Start Date 2024-12-15
Primary Completion 2025-12-15 (estimated)
Study Completion 2026-01-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-20